Major depressive disorder, Mental health
NMRANeumora TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Failed discontinued for Navacaprant (NMRA-140) in Major depressive disorder, Mental health. The expected timing is based on the latest available company guidance and may change.
KOASTAL program (1/2/3). 1/2/25- Reported KOASTAL-1 topline data, did not meet primary endpoint. 3/3/25- KOASTAL-2 and -3 paused and plans to make changes. 5/12/25- Resumed enrollment. 8/6/25- Topline data for -3 in Q1 2026 and -2 in Q2 2026. 11/6/25:- Enrollment ongoing in KOASTAL Ph3; KOASTAL-3 topline Q1 2026, KOASTAL-2 Q2 2026. 01/05/26:- Increasing KOASTAL-2 and -3 enrollment; consolidated Phase 3 topline data now expected in Q2 2026. 03/30/26:- KOASTAL-2/-3 fully enrolled; joint Ph3 topline data for both studies expected in Q2 2026. 05/07/26:- KOASTAL-2/-3 fully enrolled >400 pts; joint Ph3 topline readout remains expected in Q2 2026. 06/15/26:- KOASTAL-2/-3 missed primary endpoints; navacaprant development discontinued.
Verification
Confirm timing and program details against the company announcement or filing.